Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer
The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy with radiosurgery for locally advanced pancreas cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Iris C. Gibbs, MD, FACR
- George A. Fisher Jr.
- Jeffrey Norton
- Quynh-Thu Le, MD, FACR, FASTRO
- George Yang
- device : Stereotactic Radiosurgery (Cyberknife)
Phase: Phase 2
Ages Eligible For Study:
- Pancreatic tumors not to exceed 7.5 cm. - Histologically confirmed malignancies of the pancreas, (ampulla of Vater or periampullary duodenum, tumors may be included when the head of pancreas is secondarily involved and unresectable criteria are met). - Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy. CT criteria for unresectability include encasement of the superior mesenteric vein (SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery (SMA). - Patients with metastatic disease may be treated if they are symptomatic from the primary tumor. - Eastern Clinical Oncology Group performance status 0, 1 or 2.